Addressing bias and ending inequities in healthcare begins with every of us looking in the mirror. That was information through the once-a-year Hamilton Retreat attended by more than 80 Hartford Hospital doctors, leaders and board members held nearly on April 7. The occasion incorporated a dialogue amongst contributors about the vital position health care gurus and overall health methods enjoy in leading meaningful and lasting improve.
“We in healthcare know that we are aspect of this existence and loss of life predicament. We are listed here simply because we are part of a health process. And we have decades of studies that reveal unequivocally the effects of bias on life, on care, on outcomes and high quality,” said Javeed Sukhera, MD, PhD, FRCPC, Chief of Psychiatry, Institute of Residing & Chief of Psychiatry, Hartford Clinic. “Where do we go from here? We have to think about breaking that cycle of fear, labeling, avoidance and helplessness. We will need to convert to courage. We require to split the cycle by breaking the silence.”
Hartford Health care President and CEO Jeffrey Flaks has initiated a 14-stage system to address bias and well being equity throughout Hartford Health care, which contains the development of diversity councils and colleague resource groups, implicit bias training, amplified initiatives to recruit individuals of shade into management roles and the growth of our wellbeing fairness applications. Flaks states that our health technique now has a mandate to make significant modify.
“We are building excellent development in addressing diversity, inclusion and fairness on the governance and management stages. We are becoming additional reflective of the communities we serve. And, it’s crucial that we do so,” stated Flaks. “We’re pleased [with this progress] but we aren’t contented.”
The Hamilton Retreat, created by previous Clinic President Dr. T Stewart Hamilton adhering to the tragic fireplace at the medical center in 1961, is an annual gathering of Hartford Healthcare facility healthcare employees, board customers and clinic leaders to focus on what issues most to our clinic and community—“a neighborhood of fascination and a typical purpose,” as Dr. Hamilton referred to it.
“The pandemic has added an even greater level of urgency in our attempts to deal with areas these as racial inequities in health care and the want for enhanced access to our most susceptible populations,” claimed Hartford Region President Bimal Patel.
Hartford Location Board of Administrators Chair Alexia Cruz spoke about the relevance of owning a healthcare facility and board that is agent of the neighborhood.
“And as we supply on our latest value, ‘Equity’, we ought to also search in the mirror as a hospital and overall health procedure. This signifies possessing a health-related team that is fully committed and having a health-related workers that is also consultant of our group,” stated Cruz. “I can convey to by your existence listed here today that you are engaged and prepared to enable us guide these crucial variations and be certain that all of our patients are receiving the care they need to have and are entitled to.”
Dr. Sukhera was joined by Sarah Lewis, MPH, Hartford Health care Vice President of Wellness, Fairness and Inclusion in providing the keynote presentation at the digital party referred to as “Bias in the Mirror.” Lewis said making use of Hartford HealthCare’s H3W behaviors is a good basis to make significant alter.
“If we create equity into every thing we do, we can make a modify. Fairness lives in [Hartford HealthCare’s] values. We have to see this as collective operate, do the job that we’re undertaking alongside one another to assist all of us,” said Lewis.
Hartford Area Vice President of Professional medical Affairs Adam Steinberg, DO, MBA, FACOG, FACS identified as on leaders to seize the minute to initiate improve.
“As doctors and leaders we are in the historic place to make modifications that will renovate how care is shipped to individuals who have to have it most, in our most at chance communities. And we are in a posture to ensure that our treatment groups, our team, our suppliers are a improved illustration of the communities we serve. This commences with us addressing and conquering these inherent biases,” mentioned Steinberg.
A part of Alex Gregor’s childhood was spent growing up in Buncombe County, near Asheville, where he and his family enjoyed canoeing and hiking.
“I think that’s probably the origin of my environmental consciousness …those experiences with family and friends, outdoors,” he recalled recently.
After college, Gregor held several jobs before deciding to pursue a medical degree. One particular job was in the “social enterprise sector with a focus on global development issues.” He said his passion for the outdoors and his experience working on global issues carried from that career to his new one.
“Seeing the intersection of environmental challenges and human health, from that perspective, was a big part of what motivated me to go into medicine,” he said. “Specifically, to get involved in this movement of planetary health.”
Now Gregor is a fourth-year medical student at UNC Chapel Hill School of Medicine. But he noticed something missing from his medical training.
“What I saw in school was that we talked a lot about health, but not really about some of the big environmental elephants in the room, like climate change, and air pollution or other forms of pollution that really have a huge effect on health,” he said.
Public health and economic crisis
Researchers say that extreme weather events not only take a physical toll on the environment but also are responsible for causing a host of traumatic responses in people who experience the devastation, such as post-traumatic stress disorder, depression and suicide, among others.
A 2022 report published by the American Psychiatric Association, found that “67 percent of Americans agree that climate change is already impacting the population’s health.” While “55 percent of Americans are anxious about the impact of climate on their own mental health.”
What is more, in 2010, mental illness taxed the global economy by “at least $2.5 trillion in direct and indirect costs, including lost productivity and economic growth,” according to a briefing paper from The Lancet Global Health, published November 2020. The paper projects that by 2030, costs associated with mental illness will increase to $6 trillion.
Addressing the ‘elephants in the room’
In March 2020, Gregor and a group of his medical school colleagues decided it was time to act. They formed Climate Leadership & Action Network at the UNC School of Medicine (CLEAN UNC).
According to their website, the group has three primary goals: getting medical professionals up to speed on climate topics, working within the health system to reduce waste and greenhouse gasses to “do no harm” to the environment and getting the health care community involved in formulating policy solutions.
Kenan Penaskovic, associate vice-chair of clinical affairs and director of inpatient psychiatry services, was approached by CLEAN members, who had ideas about how to integrate the topic of climate and its impact on public health into a two-week elective course Penaskovic teaches titled Health and Human Behavior, he said.
“Over 200 medical and academic journals within the last year [are]simultaneously saying that the number one global public health threat is climate change,” said Penaskovic, who also said that more recently he was trying to incorporate the content into his formal teaching. “It is an acknowledgement of the fact that we’re all impacted by this and we’re all concerned.”
In a text message, Gregor said that since its founding in 2020, “more than 150 medical students and other graduate [and] undergraduate students have participated in CLEAN sponsored events (i.e. virtual lectures and discussions).” Currently, there are 778 students enrolled in the medical school, according to the registrar.
Gregor also said in the text that since the 2020-2021 academic year, “all first and second year medical students (M1s-M2s) have been taught about climate change impacts on public health in the foundation core curriculum, i.e. clinical science (including cardiovascular, pulmonary, renal and …psychiatry blocks) and social and health system courses.”
There are roughly 190 students per class.
Reduce, reuse
One goal listed on CLEAN’s website focuses on “helping the health system” reduce its carbon footprint by identifying areas where reusable items can reduce waste, for instance. In order to facilitate change at the institutional level, however, students and leaders at the school must work together.
Assistant Professor Yee Lam teaches primary care at the medical school, is CLEAN’s faculty adviser and has acted as a liaison between the group and medical school leadership.
In addition to advocating for elective courses that address climate change, CLEAN offers an environmental impact evaluation.
“There is this planetary health report card that comes out and kind of gives an assessment of where your institution is at the moment on a variety of factors,” Lam said.
One of the issues CLEAN is exploring with the administration is whether sustainable practices can be enhanced in the clinical setting by partnering with vendors that use less of the “superfluous packaging” that comes along with the many medical supplies used daily in health care settings.
Biomedical waste generated daily at medical centers across the country. Image source: MFERMION/ Wikimedia Commons
There are five medical schools in North Carolina, but it’s not clear whether any of the others offer any coursework on the impacts of climate change.
A spokeswoman from East Carolina University’s Brody School of Medicine said the school currently doesn’t offer any coursework on the impacts of climate change on public health. Campbell University School of Osteopathic Medicine, Wake Forest University School of Medicine and Duke University School of Medicine did not respond to requests for comment.
A national movement
The idea of addressing the impacts of climate change on public health in medical school curricula appears to be spreading across the country.
Last month, Lisa Doggett, co-founder and president of the board of directors of Texas Physicians for Social Responsibility (PSR), announced in a press release that three Texas Medical schools – Dell Medical School at the University of Texas at Austin, Baylor College of Medicine in Houston and University of Texas Southwestern in Dallas – are offering an elective course on “environmental threats, including climate change.”
“The elective courses were developed by Texas PSR, a nonprofit organization and a chapter of National PSR dedicated to addressing the gravest threats to human health, including climate change,” Doggett said in an email.
Doggett said what motivated her to collaborate with her colleagues to develop the course was inspired by the fact that when she attended medical school in the mid-1990s, environmental health training was not offered.
“I worked in community clinics, providing patient care, but I realized my ability to help my patients was limited in many ways,” she said. “We’ve learned that most of what determines someone’s health status comes from their environment and the conditions in which they live, not what a doctor can do for them in a clinic.”
When asked why it is important for medical students to take courses on the impacts of climate on public health, Doggett emphasized the role of medical doctors in educating patients.
“Physicians are well-positioned to help patients connect the dots between climate change and their own health and personal choices,” said Doggett. “We are also respected community leaders who can be impactful advocates for change at the policy level and with decision-makers and elected officials.”
Republish our articles for free, online or in print, under a Creative Commons license.
X
Republish this article
As of late 2019, we’re changing our policy about reprinting our content.
You are free to use NC Health News content under the following conditions:
You can copy and paste this html tracking code into articles of ours that you use, this little snippet of code allows us to track how many people read our story.
Please do not reprint our stories without our bylines, and please include a live link to NC Health News under the byline, like this:
By Jane Doe
North Carolina Health News
Finally, at the bottom of the story (whether web or print), please include the text:
North Carolina Health News is an independent, non-partisan, not-for-profit, statewide news organization dedicated to covering all things health care in North Carolina. Visit NCHN at northcarolinahealthnews.org. (on the web, this can be hyperlinked)
by Will Atwater, North Carolina Health News April 11, 2022
Disclosures:
Armstrong reports she is a research investigator and scientific advisor to AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo, Lilly, Menlo, Merck, Modernizing Medicine, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi and Modmed.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Although multiple therapies, including systemic and biologic treatments, are effective in treating psoriasis, topical agents are an important component of psoriasis management, according to April W. Armstrong, MD.
“Topical therapy has always been a keystone of therapy for patients with more limited psoriasis,” Armstrong, professor of dermatology and associate dean at Keck School of Medicine at USC, told Healio.
April W. Armstrong
To address the significant advances in research made in topical therapy, the American Academy of Dermatology and the National Psoriasis Foundation released joint guidelines on the use of these agents in 2020. In addition, the guideline authors recognized the growing popularity of alternative medicine and sought to discuss its role in psoriasis management.
In an interview with Healio, Armstrong, who helped author the guidelines, discussed some of the key recommendations regarding use of topical agents and alternative medicine as well as which tools may be most useful for gauging psoriasis disease severity.
Healio: What prompted drafting the guidelines?
Armstrong: First, topical agents have always played a role for patients with more limited psoriasis, so drafting and updating of the previous guidance on topical therapy was necessary to really reflect development in this exciting area.
Second, there have also been several different developments in terms of alternative therapies or approaches to treating psoriasis. Consequently, the guidelines committee felt it was necessary to address alternative medicine to better inform our clinicians, who will likely be asked questions about these treatments, as well as benefit the community in general.
Finally, the third part of the guidelines focuses on different psoriasis disease severity measures. Again, there has been tremendous development in this area, so we thought it was important to review these measurements and discuss their relevance in the clinical setting as well as the trial setting. This is important to help us monitor our patients’ psoriasis journey, but we also hope it will be informative for clinical trials as we evaluate different therapies.
Healio: What are the most important recommendations with respect to topical therapies?
Armstrong: We covered a number of different areas in our section on topical therapies. All are significant, but I will highlight two that are particularly important.
First, we emphasize that topical steroids remain an effective and safe therapy for many patients with mild to moderate psoriasis. This is important because our patients often come across information saying that we still need more research concerning the benefits and side effects of topical steroids. After evaluating rigorous literature, the committee believes topical steroids still play an important and major role in management of limited psoriasis, and when used appropriately under the direction of dermatologists, they can still be quite effective.
Second, we introduced the concept of proactive management, which arises from the understanding that psoriasis is a chronic disease that tends to occur and recur in the same areas for a person. This strategy involves treating psoriasis plaque to clear or almost clear during a flare and then applying a topical non-corticosteroid, such as a vitamin D analog or calcineurin inhibitor, to the area where the patient often experiences flare. However, instead of applying the treatment every day, the patient would do so maybe twice a week. This approach can reduce the number of flares as well as reduce the amount of medication that a patient is likely to use in the long term, so it is important that both clinicians and patients be aware of this strategy.
I would also like to mention some “oldies but goodies” in terms of treatment. For instance, long-term studies have shown that topical vitamin D analogs are still very safe and can typically be used in larger quantities — potentially up to 100 g per week — in adults. We also specifically reemphasized that calcineurin inhibitors, such as tacrolimus or pimecrolimus, also remain safe when used topically. Back in 2005, the FDA added a boxed warning to calcineurin inhibitors regarding the risk for lymphoproliferative disorder. However, this was related to systemic exposure in animals, and, to date, there is no signal or safety concern with the topical use of calcineurin inhibitors for psoriasis.
Finally, the guidelines address the use of combination topical therapy, which typically combines a topical steroid with a non-steroid agent, such as a topical vitamin D analog or a topical keratolyic agent. The advantage of many of these topical combination therapies is that the effects are quite synergistic, meaning they are generally more effective than either ingredient alone. Additionally, they often only require once daily dosing, so adherence is usually good among patients.
Healio: What do the guidelines say regarding the use of topical therapies in combination with biologic or systemic therapies?
Armstrong: Topical therapies make a good adjunct to biologic therapies or oral systemic therapies. For instance, a patient may be on a primary systemic agent — be it a biologic or oral systemic therapeutic agent — and may not achieve clearance to the degree that they would like. This would be a great opportunity to add a topical therapy to help reduce psoriasis severity in the hard-to-treat areas, such as the lower extremities. Often, we do not have the luxury of being able to switch a patient to another biologic due to their insurance or other barriers to access, in addition to the fact that they are reaping significant benefit from their current biologic. Therefore, the strategy here is to intensify topical treatment in those localized areas so that the patient can achieve clear or almost clear skin and be able to enjoy their life without feeling uncomfortable about their skin. This type of combination therapy is a good option, especially when the patient is achieving relatively good control of their psoriasis with the primary systemic agent.
Healio: What would you say are the most important recommendations regarding alternative medicine?
Armstrong: We covered several different topics in our section on alternative medicine and I encourage readers to review all of them. However, I will highlight a few that I believe are interesting.
One area that we covered in the guidelines is traditional Chinese medicine. Several studies have shown that traditional Chinese medicine yields some benefit in psoriasis, but most of these studies were not standardized in terms of measurements or methodology, which made it difficult to synthesize the data. In addition, traditional Chinese medicine is often an umbrella term used to describe various types of therapies, so we need more data and probably specialists in herbology to weigh in while we evaluate some of those data the next time around.
We also looked at a few other agents. Aloe vera and St. John’s wort, for example, have both shown some efficacy in patients with mild psoriasis. Again, though, we don’t have large studies with alternative medicines, and it would be a luxury to even have controlled studies, so although we recognize there may be some benefit to using these treatments in some patients, by and large, alternative medicine should really be considered as an adjunct to FDA-approved therapies. The reason for this is that the evidence for FDA-approved therapies is very robust while the level of evidence that we have for alternative medicine is just not there yet.
Also, it’s imperative for our patients to recognize that alternative medicine is not without risks. The guidelines contain a section in which we discuss not only the potential benefits, but the risks associated with using these alternative therapies. This is very important to take into consideration as patients may often be unaware of some of the risks of alternative medicine because they perceive them to be “natural.” However, one should always be aware of the potential risks, especially of anything that is taken in larger quantities.
In addition, we reviewed the role of diet as well as different supplements for psoriasis management. At the current time, the conversation around omega-3 oil remains controversial. There is evidence both for and against its use, meaning that the evidence does not support its beneficial effects in psoriasis. Evaluating the data here can be difficult because a lot of studies use different doses and different types of omega-3 oil that is refined in different ways, so we currently do not support the use of omega-3 oil as a monotherapy for psoriasis. Again, if patients want to add it on to their regular medical therapy for psoriasis to see if they may benefit, they can, but there are concerns about mercury toxicity and other risks depending on the way in which the fish oil is extracted.
Oral vitamin D supplementation is also quite interesting. We know topical vitamin D supplementation, when formulated in the right fashion, is effective in treating psoriasis. However, the doses of oral vitamin D supplementation that were studied for psoriasis have not uniformly shown a significant benefit. Therefore, we again would not recommend oral vitamin D as a full treatment for psoriasis. Certainly, there are other health benefits to vitamin D supplementation, but when we’re looking at oral vitamin D for the treatment of psoriasis, we should inform our patients that the expectations should be a little bit muted.
The last thing that I’ll highlight is the gluten-free diet because we get a lot of questions about this one from our patients. Based on our current understanding, the evidence does not support the independent significant benefit of a gluten-free diet for patients with psoriasis who have no history of celiac disease. However, if a patient has psoriasis as well as confirmed celiac disease, a gluten-free diet would be helpful. In those patients — who are actually few and far between — there is likely a much stronger connection between psoriasis and a gluten-free diet than in the majority of patients for whom that particular connection might be a bit more tenuous.
Healio: How do the guidelines recommend that physicians assess disease severity?
Armstrong: For psoriasis disease severity, we highlighted several different instruments in the guidelines, but we emphasize that there are three kinds of elements of defining psoriasis: what it looks like on the skin, which we as clinicians can observe; the symptoms, such as itching, burning and stinging; and how psoriasis impacts quality of life, including the effects on a patient’s work or personal relationships. It is important to take all three of those components into consideration.
So, when we’re looking for signs of psoriasis, body surface area (BSA) is still one of the most useful measures for disease severity. Now, obviously, it is not all-encompassing and has its limitations, but it is very easy to use. When we think about 1{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of BSA essentially being the area of the patient’s handprint, it is easier to explain to our patients and easy to assess in the clinic. Therefore, the guidelines reiterate the utility of BSA in the clinical context. In addition to that, we have the Physician Global Assessment where we rank the disease severity from clear to severe using a five-point scale, which is also easy to use and is helpful in terms of clinical utility.
There are other measures, including the Psoriasis Area and Severity Index (PASI), which is used ubiquitously in clinical trials. However, although it’s very sensitive and responsive to change, it is not that easy to do clinically. Therefore, in the guidelines, we recognize that the utility of instruments such as PASI is most evident in clinical trial settings and perhaps less so in clinical settings unless a clinician is asked to use it to access to a medication, for example.
Healio: Did the guideline authors identify areas that necessitate further research?
Armstrong: Yes. We determined that we will need more evidence in all three areas that we discussed.
In terms of FDA-approved topical therapies, the focus will be on non-steroidal topical agents that can be helpful in treating our patients with psoriasis. Additionally, the long-term use of topical agents is an area of interest as well.
Regarding alternative medicine, it’s still a little bit of a ‘Wild West.’ We would love to have more research into the various agents out there to understand more precisely their efficacy and safety profiles so that we can inform our patients appropriately.
Finally, in the area of psoriasis disease severity measurements, our field has come a long way in understanding disease burden and how to measure it. For example, last year, the International Psoriasis Council put out an article looking at psoriasis disease severity based on two categories: patients who are candidates for topical therapies and patients who are candidates for systemic therapy. So, there are a number of different movements trying to address some of our gaps in knowledge and more comprehensively capture the disease burden experienced by our psoriasis patients.
